Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
DNA Script logo — Transforming how molecular biology translates to human healt...

DNA Script

Transforming how molecular biology translates to human health, personalized medicine and synthetic biology

Founded 2014 France France 132 employees Series C Total: $310.20M Biotechnology, Health Care +1

General Information

Company Name DNA Script
Founded Year 2014
Location France France
Employees 132
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series C
Business Model B2B, D2C, SaaS
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with DNA Script. To contact DNA Script, visit dnascript.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DNA Script compare?

A PDF of DNA Script and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DNA Script soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DNA Script

DNA Script is set on a transformative path in the biotechnology sector, particularly impacting molecular biology and personalized medicine. Founded in 2014 and headquartered in France, this company aims to redefine DNA synthesis through innovative enzymatic methods.

Their primary product, SYNTAX™️, positions them at the forefront of genomic research, offering a benchtop DNA printer powered by enzymatic technology. This innovation marks a significant leap in enzyme engineering and surface and nucleotide chemistries, which are critical for advancements in synthetic biology and health care.

DNA Script's vision has attracted substantial financial backing, evidenced by their recent $35.00M Series C investment received on 01 January 2022 from notable investors such as T. Rowe Price, Baillie Gifford, eureKARE, Healthcor Management, and Irving Investors. Positioned within the biotechnology, health care, and life sciences industries, DNA Script remains a compelling opportunity for those investing in groundbreaking genomic technologies.

Business keywords: DNA Synthesis, Enzymatic Technology, Synthetic Biology, Personalized Medicine, Genomics Research, Life Science, Molecular Biology, Instrumentation Innovation, Enzyme Engineering, Surface Chemistry, Nucleotide Chemistry, Benchtop DNA Printer, Research and Development, Biotech Disruption

Services & Products

In-house DNA Synthesis
SYNTAX Platform
Custom DNA Production
Synthetic Biology Workflow Optimization

Target Customers

dsDNA Providers Contract Research Organizations (CROs) Core Facilities Biotech Companies Pharmaceutical Companies Governmental Agencies

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $35.00M 5
T. Rowe Price Baillie Gifford eureKARE
T. Rowe Price, Baillie Gifford +3
01 Jan 2022
Series C $165.00M 16
Bpifrance Casdin Capital Coatue
Bpifrance, Casdin Capital +14
01 Oct 2021
Series B $50.00M 6
Bpifrance Casdin Capital Illumina Ventures
Bpifrance, Casdin Capital +4
01 Jul 2020
Series B $38.50M 7
Bpifrance Kurma Partners Sofinnova Partners
Bpifrance, Kurma Partners +5
01 May 2019
Grant $2.70M 1
Bpifrance
Bpifrance
01 Jul 2018
Grant $5.50M 2
Bpifrance European Innovation Council
Bpifrance, European Innovation Council
01 Apr 2018
Series A €11.00M 5
Kurma Partners Sofinnova Partners Illumina Ventures
Kurma Partners, Sofinnova Partners +3
01 Sep 2017
Support Program Undisclosed 1
Paris Biotech Santé
Paris Biotech Santé
01 Jan 2017
Seed €2.50M 3
Kurma Partners Sofinnova Partners
Kurma Partners, Sofinnova Partners +1
01 Jun 2016
Support Program Undisclosed 1
AGORANOV
AGORANOV
01 Jun 2015

View All 11 Funding Rounds

DNA Script Alternatives & Competitors

View All Alternatives
DNA Script vs
Ansa Biotechnologies, Inc.
Ansa Biotechnologies, Inc. United States

High-fidelity DNA synthesis using enzymes

Series B
82 employees
Biotechnology, Health and Wellness
Compare DNA Script vs Ansa Biotechnologies, Inc.
DNA Script vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
Compare DNA Script vs Synbio Technologies
DNA Script vs
ELEGEN
ELEGEN United States

Unlock the promise of synthetic biology by accelerating the Design-Build-Test-Learn cycle

Series B
81 employees
Biotechnology, Health Care
Compare DNA Script vs ELEGEN
Also compare with: DNA Script vs Molecular Assemblies, Inc. Molecular Assemblies, Inc. DNA Script vs Evonetix Ltd Evonetix Ltd View all alternatives

FAQ About DNA Script

Transforming how molecular biology translates to human health, personalized medicine and synthetic biology
DNA Script was founded in 2014.
DNA Script is headquartered in France.
DNA Script operates in Biotechnology, Health Care and Life Sciences. Its work centres on DNA Synthesis, Enzymatic Technology, Synthetic Biology and Personalized Medicine. Its customers include dsDNA Providers, Contract Research Organizations (CROs) and Core Facilities.
DNA Script has a B2B, D2C and SaaS business model. Its revenue comes from Product Sales, Licensing and Service Fee.
DNA Script has approximately 132 employees.
DNA Script has completed 11 funding rounds, raising a total of $310.20M. The latest funding stage is Series C.
DNA Script offers: In-house DNA Synthesis, SYNTAX Platform, Custom DNA Production, Synthetic Biology Workflow Optimization.
Top alternatives and competitors to DNA Script include Ansa Biotechnologies, Inc., Synbio Technologies, ELEGEN, Camena Bioscience, Molecular Assemblies, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DNA Script and Ansa Biotechnologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DNA Script, https://bouncewatch.com/company/dna-script-1, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes